Xiao F, Xiao W, Li X, Li R, Zhao K. Cost-effectiveness analysis of Trastuzumab Deruxtecan as second-line treatment for HER2- positive advanced breast cancer. Health Decision. 2024;2(S1). doi:10.54844/hd.2024.0009